10x Genomics stock reaches 52-week high at $66.95

10x Genomics Inc (TXG) stock reached a 52-week high of $66.95, reflecting strong performance and positive analyst outlooks. The company's market capitalization stands at $8.71 billion. The stock has seen significant returns, with a 1-year total return of 385.93% and a year-to-date return of 302%. In the second quarter of 2026, the company reported revenue of $151.04 million, surpassing expectations of $146.64 million, and an adjusted loss per share of $0.14, better than the projected $0.24 loss. Analysts have raised their price targets and maintained positive ratings. Stifel reiterated a Buy rating, RBC Capital initiated coverage with a Sector Perform rating, and Canaccord raised its price target from $50 to $60, maintaining a Buy rating. The stock's beta, a measure of volatility, is 2.08. Despite the strong performance, the company's outlook appears softer due to its transition to the new Atera platform. InvestingPro analysis lists the stock as overvalued relative to its fair value, placing it among the "Most Overvalued" list.